Novocure Ltd. reported financial results for the second quarter ending June 30, 2025. The company's total net revenues for the quarter reached $158.8 million, marking a 6% increase compared to the same period in 2024. This growth was primarily driven by an increase in active patient numbers across major markets. The United States contributed $94.3 million to the revenues, with Germany, France, and Japan contributing $19.1 million, $18.4 million, and $9.5 million, respectively. Other active markets added $13.0 million, and revenue from Greater China, through Novocure's partnership with Zai Lab, totaled $4.6 million. Revenue from Optune Lua® was $2.4 million for the quarter, with $1.1 million from non-small cell lung cancer (NSCLC) and $1.3 million from malignant pleural mesothelioma (MPM). The gross margin for the quarter stood at 74%, down from 77% in the previous year, influenced by the introduction of the Head Flexible Electrode transducer array for Optune Gio® and the launch of NSCLC treatment, which is seeing on-label patients treated at risk ahead of broad reimbursement, along with increased tariffs. Novocure also highlighted its progress in clinical trials, with results from the Phase 3 PANOVA-3 clinical trial presented at the 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress, selected as Best of ASCO 2025, and published in the Journal of Clinical Oncology. CEO Ashley Cordova emphasized the company's strategic positioning with ongoing and upcoming product launches in the glioblastoma and non-small cell lung cancer sectors, aiming to expand Tumor Treating Fields therapy to new patient populations.